Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Spinal Cord Stimulation for the Treatment of Major Depressive Disorder [Phase 1, Phase 2]
Completed Phase 1 and Phase 2 clinical trials evaluating spinal cord stimulation for major depressive disorder, with results posted.
-
FDA approval · 2024-04-19FDA Approved: CELEXA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Celexa (citalopram) submitted by Allergan, Inc.
-
FDA approval · 2024-04-19FDA Approved: LEXAPRO — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Lexapro (escitalopram) submitted by Allergan, Inc., advancing a labeling action for the product.
-
FDA approval · 2024-04-19FDA Approved: VIIBRYD — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for VIIBRYD (vilazodone hydrochloride) from Allergan, Inc.
-
FDA approval · 2024-04-19FDA Approved: FETZIMA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for FETZIMA (levomilnacipran hydrochloride) from Allergan, Inc. The action constitutes an additional…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-04-19Clinical Trial Update: The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density [Phase 2]
A Phase 2 clinical trial evaluating the effect of psilocybin on symptom severity and synaptic density in major depressive disorder.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study of Xiongdan Wan Treating Depression [Phase 2]
Phase 2 clinical trial completed examining Xiongdan Wan for major depressive disorder.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: Middle School Success Over Stress [NA]
A completed clinical trial from the University of Oregon evaluated a program addressing parenting and parent-child relations, with results p…
-
CLINICAL_TRIALS trial_result · 2024-04-17Clinical Trial Update: Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide [Phase 2]
Phase 2 trial evaluating three fixed doses of intranasal esketamine added to comprehensive standard of care for rapid reduction of symptoms …
-
FDA approval · 2024-04-16FDA Approved: CITALOPRAM — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for citalopram from Cipla USA Inc., authorizing changes to the drug's labeling.
-
FDA approval · 2024-04-15FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for escitalopram oxalate from Amneal Pharmaceuticals LLC, approving a generic version of escital…
-
CLINICAL_TRIALS trial_result · 2024-04-11Clinical Trial Update: Buspirone and Melatonin for Depression Following Traumatic Brain Injury [Phase 4]
Phase 4 trial evaluating buspirone and melatonin for Depression following traumatic brain injury; recruiting.
-
CLINICAL_TRIALS trial_result · 2024-04-09Clinical Trial Update: OptimizeD Pilot Study [Phase 3]
Phase 3 pilot study update for OptimizeD completed, investigating depression and depressive disorder.
-
CLINICAL_TRIALS trial_result · 2024-04-08Clinical Trial Update: Deep Brain Stimulation for Major Depressive Disorder [NA]
Clinical trial update indicates termination of a deep brain stimulation study for major depressive disorder with results posted.
-
FDA approval · 2024-04-05FDA Approved: FLUOXETINE — Original Application (Strides Pharma Science Limited)
FDA approved an Original Application for a generic Fluoxetine from Strides Pharma Science Limited, enabling a generic version of fluoxetine …
-
FDA approval · 2024-04-03FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Bupropion hydrochloride sustained-release (Actavis) under an ANDA, approving the supplemental fi…
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Mini Theta Burst TMS in MDD Patients [NA]
A completed clinical trial report on mini theta burst TMS in patients with Major Depressive Disorder; results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-04-01Clinical Trial Update: A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine [Phase 4]
A Phase 4 randomized, double-blind, placebo-controlled trial evaluated augmentation with agomelatine in adults with major depressive disorde…
-
FDA approval · 2024-03-28FDA Approved: CITALOPRAM — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved a supplemental application for citalopram by Torrent Pharmaceuticals Limited, indicating an approved change related to the …
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients [Phase 1, Phase 2]
Clinical Trial Update reports phase 1/2 study of SPL026 (DMT Fumarate) in healthy subjects and patients with Major Depressive Disorder, with…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) [Phase 3]
Phase 3 trial evaluating REL-1017 as adjunctive therapy for major depressive disorder; results and safety data were posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) [Phase 3]
Phase 3 trial assessing REL-1017 as monotherapy for major depressive disorder has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder [Phase 1, Phase 2]
A clinical trial update for CYB003 (a psilocybin analog) in healthy participants with and without major depressive disorder, covering Phase …
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: Self-Management of Chronic Depressive Symptoms in Pregnancy [NA]
A completed clinical trial investigating self-management of chronic depressive symptoms in pregnancy was conducted, with results posted.
-
FDA approval · 2024-03-21FDA Approved: ESCITALOPRAM ORAL SOLUTION — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for escitalopram oral solution from Chartwell RX, LLC, recognizing a generic formulation.